Price And Quantity
  • 1
  • Box/Boxes
  • 10000 INR
Product Specifications
  • Pharmaceutical
  • External Use Drugs
  • Tablets
  • Suitable For All Ages, Women, Adult, Children, Infants
  • 60 mg
  • Dry Place
    Product Description
    MyDekla is demonstrated for use with sofosbuvir for the treatment &amp of patients with constant HCV genotype 3 contamination. Maintained virologic reaction (SVR) rates are decreased in HCV genotype 3-tainted patients with cirrhosis getting this regimen. Treatment with MyDacla ought to be started &amp and checked by a doctor experienced in the administration of unending hepatitis C.

    Daclatasvir is one of the new direct-acting antiviral medications that objective distinctive strides of the hepatitis C infection (HCV) lifecycle. It is the first-since forever endorsed &amp HCV NS5A replication complex inhibitor, which means it meddles with a protein the infection uses to recreate.

    Daclatasvir is demonstrated for use by grown-ups with unending hepatitis C, which means disease enduring over six months. It is endorsed for individuals with HCV genotype 1, 2, 3 or 4. Genotype 1 is the most widely recognized sort in Europe and considered the hardest to treat.

    Daclatasvir can be utilized by individuals being dealt with for hepatitis C surprisingly (known as ‘treatment-innocent’) and for retreatment of individuals who were not cured with past interferon-based treatment (known as ‘treatment-experienced’).

    • Drug Name: Mydacla
    • Non specific Name: Daclatasvir Dihydrochloride
    • Organization Name: Mylan
    • Accessible as (Form and Strength): 60 mg tablets

    Trade Information
    • Letter of Credit (L/C)
    • 100 Per Week
    • 2-3 Days
    • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
      Contact Us

      16/8, Old Rajinder Nagar, New Delhi, Delhi, 110060, India
      Phone :+918037301152